FDA clears Circadia Health’s respiratory monitoring platform

Circadia Health has received expedited Food and Drug Administration (FDA) clearance for Contactless Respiration Rate (CResp) monitoring systems amid the Covid-19 outbreak.

The platform saves patient lives by forecasting and eliminating respiratory complications through early warning scores and allowing timely clinician interventions.

The C100 system uses proprietary radar Signal Analysis Technology (rSAT) and cloud-based software for the early detection of patient deterioration to accelerate clinical decision-making.

CRespis is accurate, reliable, easy-to-use and scalable for both continuous and spot-check monitoring of early patient deterioration signs such as respiratory rate.

It provides long-term respiration data to allow effective triage and ongoing care management.

In addition to CResp, the Circadia rSAT and artificial intelligence (AI)-powered algorithms provide monitoring of motion, presence and sleep quality, as well as ambient sound and light monitoring for detecting disturbances and coughing.

Furthermore, C100 is said to improve patient outcomes, as well as reduce readmissions and the risk of infection transmission from patient-to-patient and patient-to-clinician.

Circadia Health co-founder and CEO Fares Siddiqui said: “Our goal is to provide a frictionless solution to clinicians in order to help improve patient outcomes and reduce the cost of care.

“During this Covid-19 crisis, the FDA has recognised the life-saving potential of our technology. We are now able to deliver the most convenient and powerful method to monitor fragile patients both in-facility and remotely at home.”

The company noted that it will soon roll out the C100 system to help hospitals and skilled nursing facilities contain respiratory-related illnesses such as Covid-19, pneumonia, chronic obstructive pulmonary disease (COPD) exacerbations and other forms of respiratory failures.